Nektar Therapeutics (NASDAQ:NKTR)
| CAPS Rating |
|
|---|
NKTR
VS S&P 500 (SPY)
NKTR News and Commentary
- Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 2 – SeekingAlpha
- An Early Look at 2012 ASCO Biotech Cancer Stocks (DNDN, LLY, AMGN, ARIA, ARQL, ARRY, AVEO, BVTI, ABP – 247wallst
- Taking An Early Look at 2012 ASCO Biotech/Cancer Stocks (DNDN, LLY, ARIA, ARRY, BVTI, ABPI, CLDX, CY – 247wallst
- Nektar Therapeutics Beats Up on Analysts Yet Again – The Motley Fool
- 1 Biotech With Room to Run – The Motley Fool
- Charting a Course to Profit – The Motley Fool
- Will the FDA Approve MAP's Levadex? – The Motley Fool
- Make Money in Biotech and Genome Stocks the Easy Way – The Motley Fool
- Nektar Therapeutics Catches Analysts Sleeping Again – The Motley Fool
How do you think NKTR will perform against the market?
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
Powered by: CAPSAll Players
193
Outperform
28
Underperform
All-Star Players
40
Outperform
12
Underperform
Wall Street
8
Outperform
1
Underperform
RSS Headlines
Fool UK
